GBS Inc. is on a mission to put the power of non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at point of care. With the world-first Biosensor Platform, GBS Inc. is developing and launching diagnostic tests urgently needed to help eradicate COVID-19 and change the lives of people living with diabetes.
Company profile
Ticker
GBS
Exchange
Website
CEO
Harry Simeonidis
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
3M • Baxter International • Boston Scientific • Stryker • Becton, Dickinson And • Teleflex • Resmed • Haemonetics • Hill-Rom • Nuvasive ...
Former names
Glucose Biosensor Systems (Greater China) Holdings, Inc.
SEC CIK
Corporate docs
Subsidiaries
Glucose Biosensor Systems (APAC) Pty Ltd • GBS Operations Inc. ...
IRS number
821512711
GBS stock data
News
GBS Announces Key Milestone In Prospective Study Comparing Glucose In Oral Fluids And Blood
13 Jul 22
3 Stocks Under $2 Insiders Are Aggressively Buying
23 Jun 22
GBS: GBS' Prints Are All Over It
22 Jun 22
GBS Inc. Enters Exclusivity Agreement With Intelligent Fingerprinting Limited In Respect Of GBS's Proposed Acquisition Of IFP
16 Jun 22
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
14 Jun 22
Press releases
GBS Inc. Announces Key Milestone in Prospective Study Comparing Glucose in Oral Fluids and Blood
13 Jul 22
GBS Inc. to Initiate Manufacturing on the University of Newcastle Australia Campus
23 Jun 22
GBS INC. Announces Adjournment of 2022 Annual Meeting of Stockholders to July 13, 2022
16 Jun 22
GBS Inc. Enters into Exclusivity Agreement for an Acquisition of Unique Point of Care Diagnostic Screening Technology Focused on Opioids and Drugs of Abuse
16 Jun 22
Calendar
16 May 22
15 Aug 22
30 Jun 23
Financial summary
| Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Jun 21 | |
|---|---|---|
| Revenue | ||
| Cost of revenue | ||
| Operating income | ||
| Operating margin | ||
| Net income | ||
| Net profit margin | ||
| Cash on hand | ||
| Change in cash | ||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 10.76M | 10.76M | 10.76M | 10.76M | 10.76M | 10.76M |
| Cash burn (monthly) | 144.84K | 292.13K | 447.61K | 591.79K | 448.04K | 464.6K |
| Cash used (since last report) | 650.9K | 1.31M | 2.01M | 2.66M | 2.01M | 2.09M |
| Cash remaining | 10.11M | 9.44M | 8.74M | 8.1M | 8.74M | 8.67M |
| Runway (months of cash) | 69.8 | 32.3 | 19.5 | 13.7 | 19.5 | 18.7 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 22 Jun 22 | Spiro Kevin Sakiris | Common Stock | Buy | Acquire P | No | No | 0.6498 | 5,000 | 3.25K | 50,228 |
| 17 Jun 22 | Spiro Kevin Sakiris | Common Stock | Buy | Acquire P | No | No | 0.6115 | 15,970 | 9.77K | 45,228 |
| 17 Feb 22 | Life Science Biosensor Diagnostics Pty | Common Stock | Sell | Dispose S | No | No | 0.51 | 576,028 | 293.77K | 1,081,804 |
| 16 Feb 22 | Life Science Biosensor Diagnostics Pty | Common Stock | Sell | Dispose S | No | No | 0.63 | 100,000 | 63K | 1,657,832 |
| 15 Feb 22 | Life Science Biosensor Diagnostics Pty | Common Stock | Sell | Dispose S | No | No | 0.68 | 100,000 | 68K | 1,757,832 |
| 14 Feb 22 | Life Science Biosensor Diagnostics Pty | Common Stock | Sell | Dispose S | No | No | 0.7 | 100,000 | 70K | 1,857,832 |
| 11 Feb 22 | Life Science Biosensor Diagnostics Pty | Common Stock | Sell | Dispose S | No | No | 0.75 | 100,000 | 75K | 1,957,832 |
Institutional ownership, Q1 2022
3.6% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 14 |
| Opened positions | 13 |
| Closed positions | 1 |
| Increased positions | 1 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 416K |
| Total shares | 533.71K |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Geode Capital Management | 113.12K | $88K |
| VIRT Virtu Financial | 89.39K | $70K |
| Renaissance Technologies | 67.5K | $53K |
| Bridgeway Capital Management | 50K | $39K |
| GS Goldman Sachs | 42.8K | $33K |
| Two Sigma Securities | 36.12K | $28K |
| BLK Blackrock | 31.17K | $24K |
| Citadel Advisors | 29.42K | $23K |
| Millennium Management | 28.48K | $22K |
| IHT Wealth Management | 20K | $16K |
Financial report summary
?Management Discussion
- Government support income increased by $1,910,663 to $1,980,484 from $69,821 for the year ended June 30, 2021 compared to same period in 2020. This increase was primarily attributable to GBS Inc.’s subsidiary companies having received and entitlements to receive Research and Development tax incentives. The purpose of the grant is to incentivize companies with their research and development related activities and other COVID-19 related government support in the current period where the companies are located.
- Shared service revenue was zero and $118,923 for the year ended June 30, 2021 and 2020, respectively. Shared service revenue is mainly attributable to the recovery of costs from related parties. There were no shared services in the current period.
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
absorb, attention, bandwidth, bid, blook, brought, calendar, consecutive, cure, damage, Dec, defend, delisting, discrimination, economic, employment, enterprise, family, harassment, hour, illegal, immaterial, inconsistent, intention, leave, letter, liable, litigation, Nasdaq, notice, notifying, obligation, preceding, privacy, QA, receipt, regain, representation, reputation, residual, split, termination, trading, ultimately, unfair, unfounded, unwinding, vacation, VIE, violation, wage, written, wrongful
Removed:
assay, Biologically, blood, collected, demonstrated, detect, greatly, Harvard, indirect, Inspired, Institute, John, observed, scale, seroconvert, serum, study, susceptibility, susceptible, symptom, temporal, validation
Financial reports
Current reports
8-K
Amendments to Articles of Incorporation or Bylaws
21 Jul 22
8-K
GBS Inc. Enters into Exclusivity Agreement for an Acquisition of
16 Jun 22
8-K
GBS Inc. Reports Third Quarter 2022 Financial Results and Recent Business Highlights
11 May 22
8-K
Departure of Directors or Certain Officers
29 Apr 22
8-K
GBS Inc. Announces Institutional Review Board Approval to Initiate Clinical Trial at Sutter Health Mills-Peninsula Medical Center
1 Apr 22
8-K
Departure of Directors or Certain Officers
24 Mar 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
23 Mar 22
8-K
Departure of Directors or Certain Officers
28 Feb 22
8-K
GBS Inc. Reports Second Quarter 2022 Financial Results and Recent Business Highlights
10 Feb 22
8-K
GBS Inc. Announces Application for FDA Breakthrough Device Designation to Fast Track Rapid Saliva Glucose Test
16 Dec 21
Registration and prospectus
S-8
Registration of securities for employees
5 Aug 22
S-3
Shelf registration
8 Apr 22
S-1
IPO registration
20 Jan 21
424B4
Prospectus supplement with pricing info
27 Dec 20
S-1MEF
Registration of additional securities for an S-1
22 Dec 20
8-A12B
Registration of securities on exchange
22 Dec 20
S-1/A
IPO registration (amended)
20 Dec 20
FWP
Free writing prospectus
7 Dec 20
Other
EFFECT
Notice of effectiveness
21 Apr 22
CORRESP
Correspondence with SEC
17 Apr 22
UPLOAD
Letter from SEC
13 Apr 22
EFFECT
Notice of effectiveness
1 Apr 21
CORRESP
Correspondence with SEC
28 Mar 21
CORRESP
Correspondence with SEC
8 Mar 21
UPLOAD
Letter from SEC
4 Mar 21
CORRESP
Correspondence with SEC
15 Feb 21
UPLOAD
Letter from SEC
3 Feb 21
EFFECT
Notice of effectiveness
23 Dec 20
Ownership
4
GBS / Spiro Kevin Sakiris ownership change
24 Jun 22
4
GBS / Spiro Kevin Sakiris ownership change
22 Jun 22
4
Change in insider ownership
22 Feb 22
4
Change in insider ownership
18 Feb 22
4
Change in insider ownership
17 Feb 22
4
Change in insider ownership
15 Feb 22
4
Change in insider ownership
11 Feb 22
4
Change in insider ownership
10 Feb 22
4
Change in insider ownership
8 Feb 22
4
Change in insider ownership
3 Feb 22
Reddit threads
Post a penny stock you think could 100x or more in 10 years. My pick $QNCCF/$QNC
24 Jul 22
DXC possible uber cannibal with 10x return potential
23 Jul 22
Daily Plays June 24, 2022
24 Jun 22
Daily Plays June 22, 2022
22 Jun 22
Daily Plays June 21, 2022
21 Jun 22
S**t ain’t getting any better.
16 Jun 22
$GBS $0.60 NASDAQ stock should easily double based on todays news they are acquiring a fingerprint sweat-based drug screening company
16 Jun 22
If I’m already down 60% am I pretty much screwed
16 Jun 22
Anybody else having to calm themselves down a bit? I'm giddy right now.
10 May 22
Daily Discussion Thread - May 10th, 2022
10 May 22